Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Englewood, Colorado and currently employs 53 full-time employees. The firm focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The firm markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The firm`s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The firm holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.
Website: aytubio.com



Growth: Bad revenue growth rate -11.5%, there is slowdown compared to average historical growth rates 36.3%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -9.1%. On average the margin is improving steadily. Gross margin is high, +70.7%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$5.89 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 47.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 104.0% higher than minimum and 98.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.2x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: AYTU
Share price, USD:  (-1.3%)3.04
year average price 2.33  


year start price 2.24 2023-03-31

min close price 1.49 2023-06-28

max close price 3.33 2023-10-18

current price 3.04 2024-03-29
Common stocks: 4 144 098

Dividend Yield:  0.0%
Last revenue growth (y/y):  -11.5%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  36.3%
Historical growth of EBITDA:  ---
EV / Sales: 0.2x
Margin (EBITDA LTM / Revenue): -9.1%
Fundamental value created in LTM:
Market Cap ($m): 13
Net Debt ($m): 9
EV (Enterprise Value): 22
Price to Book: 0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-02-14Seeking Alpha

Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript

2023-11-14Seeking Alpha

Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript

2023-09-28PennyStocks

Best Penny Stocks? 4 Hot Stocks With News This Week

2023-09-27Seeking Alpha

Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript

2023-09-21Accesswire

Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023

2023-05-11Seeking Alpha

Aytu BioPharma, Inc. (AYTU) Q3 2023 Earnings Call Transcript

2023-05-04Accesswire

Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AYTU AYTU AYTU AYTU AYTU AYTU
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-14 2023-11-14 2023-10-12 2023-05-11 2023-02-21 2022-11-14
acceptedDate 2024-02-14 16:05:58 2023-11-14 16:05:46 2023-10-12 14:50:49 2023-05-11 16:03:34 2023-02-21 16:35:37 2022-11-14 16:07:54
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
revenue 23M 22M 31M 23M 26M 28M
costOfRevenue 7M 7M 12M 10M 9M 10M
grossProfit 16M 15M 19M 13M 17M 18M
grossProfitRatio 0.707 0.669 0.604 0.561 0.658 0.652
researchAndDevelopmentExpenses 524 000 604 000 465 000 856 000 2M 1M
generalAndAdministrativeExpenses 5M 7M 6M 7M 8M 7M
sellingAndMarketingExpenses 7M 7M 8M 13M 11M 10M
sellingGeneralAndAdministrativeExpenses 12M 14M 14M 20M 19M 17M
otherExpenses -1M -709 000 -1M 1M 1M 1M
operatingExpenses 13M 15M 16M 22M 21M 20M
costAndExpenses 19M 22M 28M 32M 30M 29M
interestIncome 0 0 0 0 0 0
interestExpense 0 0 -2M -1M 3M 1M
depreciationAndAmortization 2M 2M 1M 102 000 3M 2M
ebitda 2M -2M 8M -9M -819 000 803 000
ebitdaratio 0.103 -0.068 0.261 -0.404 -0.031 0.029
operatingIncome 2M -2M 169 000 -9M -4M -2M
operatingIncomeRatio 0.103 -0.068 0.005 -0.409 -0.160 -0.055
totalOtherIncomeExpensesNet -2M -7M -5M 2M -3M -1M
incomeBeforeTax 608 000 -8M -2M -7M -7M -3M
incomeBeforeTaxRatio 0.027 -0.367 -0.080 -0.317 -0.255 -0.104
incomeTaxExpense 828 000 -2M 4M -1M 4M 1M
netIncome -220 000 -8M -2M -6M -10M -4M
netIncomeRatio -0.010 -0.367 -0.080 -0.257 -0.395 -0.153
eps -0.040 -1.480 -0.600 -1.570 -3.340 -33.660
epsdiluted -0.040 -1.480 -0.590 -1.570 -3.340 -33.660
weightedAverageShsOut 6M 5M 4M 4M 3M 125 895
weightedAverageShsOutDil 6M 5M 4M 4M 3M 125 895
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AYTU AYTU AYTU AYTU AYTU AYTU
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-14 2023-11-14 2023-10-12 2023-05-11 2023-02-21 2022-11-14
acceptedDate 2024-02-14 16:05:58 2023-11-14 16:05:46 2023-10-12 14:50:49 2023-05-11 16:03:34 2023-02-21 16:35:37 2022-11-14 16:07:54
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 20M 20M 23M 19M 20M 24M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 20M 20M 23M 19M 20M 24M
netReceivables 29M 30M 29M 34M 26M 28M
inventory 13M 13M 12M 14M 13M 13M
otherCurrentAssets 1M 749 000 868 000 1M 624 000 785 000
totalCurrentAssets 71M 71M 73M 78M 71M 74M
propertyPlantEquipmentNet 3M 4M 4M 4M 5M 6M
goodwill 0 0 0 0 0 0
intangibleAssets 56M 57M 59M 63M 65M 69M
goodwillAndIntangibleAssets 56M 57M 59M 63M 65M 69M
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 907 000 772 000 792 000 892 000 821 000 829 000
totalNonCurrentAssets 60M 62M 64M 69M 71M 76M
otherAssets 0 0 0 0 0 0
totalAssets 131M 133M 136M 147M 141M 150M
accountPayables 10M 14M 13M 15M 11M 15M
shortTermDebt 1M 1M 2M 14M 8M 9M
taxPayables 0 0 0 0 0 0
deferredRevenue 43M 41M 47M 0 0 0
otherCurrentLiabilities 9M 9M 7M 57M 49M 50M
totalCurrentLiabilities 64M 65M 69M 85M 67M 73M
longTermDebt 15M 15M 15M 11M 15M 14M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 19M 20M 13M 10M 14M -789 000
totalNonCurrentLiabilities 34M 35M 28M 21M 28M 23M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 845 000 1M 0 0 0 0
totalLiabilities 98M 101M 97M 106M 96M 96M
preferredStock 0 0 0 0 0 0
commonStock 1000.000 1000.000 1000.000 0 0 6000.000
retainedEarnings -312M -312M -304M -302M -294M -291M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0
othertotalStockholdersEquity 345M 344M 343M 343M 340M 345M
totalStockholdersEquity 33M 32M 39M 41M 46M 54M
totalEquity 33M 32M 39M 41M 46M 54M
totalLiabilitiesAndStockholdersEquity 131M 133M 136M 147M 141M 150M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 131M 133M 136M 147M 141M 150M
totalInvestments 0 0 0 0 0 0
totalDebt 16M 16M 16M 25M 22M 23M
netDebt -3M -4M -7M 6M 3M -1M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AYTU AYTU AYTU AYTU AYTU AYTU
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-14 2023-11-14 2023-10-12 2023-05-11 2023-02-21 2022-11-14
acceptedDate 2024-02-14 16:05:58 2023-11-14 16:05:46 2023-10-12 14:50:49 2023-05-11 16:03:34 2023-02-21 16:35:37 2022-11-14 16:07:54
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
netIncome -220 000 -8M -2M -7M -5M -3M
depreciationAndAmortization 2M 2M 2M 2M 2M 2M
deferredIncomeTax 659 000 -20 000 7M 0 0 0
stockBasedCompensation 820 000 930 000 900 000 902 000 3M 1M
changeInWorkingCapital -4M -1M 2M 4M -2M -10M
accountsReceivables 479 000 -945 000 5M -9M 2M -6M
inventory -117 000 -1M -622 000 -804 000 -79 000 -2M
accountsPayables -4M 914 000 -1M 5M -4M 4M
otherWorkingCapital -99 000 -297 000 -765 000 9M -336 000 -5M
otherNonCashItems 110 000 6M -326 000 -3M -709 000 311 000
netCashProvidedByOperatingActivities -135 000 -211 000 9M -3M -2M -9M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0
acquisitionsNet 0 0 -5000.000 5000.000 -5000.000 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites -174 000 -76 000 -150 000 -4000.000 0 42 000
netCashUsedForInvestingActivites -174 000 -76 000 -155 000 1000.000 -5000.000 42 000
debtRepayment -23 000 -22 000 -2M 0 0 -31M
commonStockIssued 86 000 -160 000 3M 1M 1M 10M
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -189 000 -3M -6M 1M -3M 34M
netCashUsedProvidedByFinancingActivities -126 000 -3M -5M 3M -2M 14M
effectOfForexChangesOnCash 0 0 0 0 0 0
netChangeInCash -435 000 -3M 4M -322 000 -4M 4M
cashAtEndOfPeriod 20M 20M 23M 19M 20M 24M
cashAtBeginningOfPeriod 20M 23M 19M 20M 24M 19M
operatingCashFlow -135 000 -211 000 9M -3M -2M -9M
capitalExpenditure 0 0 0 0 0 0
freeCashFlow -135 000 -211 000 9M -3M -2M -9M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-14 ET (fiscal 2024 q2)
2023 q3
2023-11-14 ET (fiscal 2024 q1)
2023 q2
2023-09-27 ET (fiscal 2023 q4)
2023 q1
2023-05-11 ET (fiscal 2023 q3)
2022 q4
2023-02-21 ET (fiscal 2023 q2)
2022 q3
2022-11-14 ET (fiscal 2023 q1)
2022 q2
2022-09-27 ET (fiscal 2022 q4)
2021 q3
2021-11-15 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-07 21:15 ET
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
2024-01-23 14:00 ET
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
2023-11-30 13:00 ET
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
2023-11-14 21:05 ET
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
2023-11-08 13:30 ET
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
2023-11-07 21:15 ET
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
2023-10-26 12:00 ET
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
2023-10-09 20:15 ET
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
2023-09-27 00:27 ET
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023
2023-09-22 00:25 ET
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
2023-09-13 12:00 ET
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
2023-07-31 12:00 ET
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
2023-07-10 12:00 ET
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
2023-06-14 12:00 ET
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
2023-06-13 17:45 ET
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
2023-06-09 12:00 ET
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
2023-05-11 20:05 ET
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
2023-05-04 20:30 ET
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
2023-05-01 12:00 ET
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
2023-04-27 12:00 ET
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
2023-02-21 21:10 ET
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
2023-02-21 20:00 ET
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
2023-02-14 13:00 ET
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
2023-02-07 13:00 ET
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
2023-01-25 13:00 ET
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
2023-01-24 13:00 ET
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
2023-01-10 13:00 ET
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
2023-01-05 21:01 ET
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
2022-11-30 13:00 ET
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
2022-11-22 21:05 ET
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
2022-11-17 13:00 ET
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row
2022-11-16 13:00 ET
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
2022-11-14 21:05 ET
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
2022-11-07 21:01 ET
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
2022-10-25 12:00 ET
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan
2022-10-13 12:00 ET
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs
2022-10-05 12:00 ET
Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions
2022-09-27 20:05 ET
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue
2022-09-20 12:00 ET
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022
2022-09-14 12:00 ET
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
2022-08-24 12:00 ET
Aytu BioPharma to Participate in September 2022 Investor Conferences
2022-08-16 12:00 ET
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
2022-08-15 20:01 ET
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
2022-08-09 13:15 ET
Aytu BioPharma Announces Pricing of Public Offering
2022-08-08 20:01 ET
Aytu BioPharma Announces Launch of Public Offering
2022-07-26 12:00 ET
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
2022-07-20 12:00 ET
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
2022-06-29 12:00 ET
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
2022-06-13 12:00 ET
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
2022-05-16 20:02 ET
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
2022-04-25 12:00 ET
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
2022-04-19 12:00 ET
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
2022-03-23 12:00 ET
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
2022-03-22 12:00 ET
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
2022-03-08 13:00 ET
Aytu BioPharma to Participate in the 34th Annual Roth Conference
2022-03-07 21:05 ET
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
2022-03-03 01:00 ET
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
2022-03-02 13:00 ET
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
2022-02-14 21:05 ET
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
2022-01-31 13:00 ET
Aytu BioPharma Completes $15 Million Debt Refinancing
2022-01-04 13:00 ET
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
2022-01-03 13:00 ET
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
2021-12-14 14:30 ET
Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome
2021-12-13 13:00 ET
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
2021-12-08 13:00 ET
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
2021-11-23 13:00 ET
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
2021-11-17 13:00 ET
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
2021-11-15 21:00 ET
Aytu BioPharma Reports First Quarter 2022 Financial Results
2021-11-08 13:05 ET
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
2021-09-30 12:01 ET
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
2021-09-27 20:01 ET
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
2021-09-23 12:00 ET
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021
2021-09-09 12:00 ET
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome
2021-09-07 12:00 ET
Aytu BioPharma to Present at Upcoming September Investor Conferences
2021-07-27 12:05 ET
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus
2021-06-28 12:50 ET
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
2021-05-25 12:01 ET
Aytu BioPharma to Present at Upcoming June Investor Conferences
2021-05-17 20:01 ET
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights
2021-05-12 14:50 ET
Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells
2021-05-10 20:01 ET
Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021
2021-04-12 12:00 ET
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
2021-04-05 12:00 ET
Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer
2021-04-01 11:30 ET
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma
2021-03-22 10:00 ET
Aytu BioScience Announces Close of Merger with Neos Therapeutics
2021-03-08 21:01 ET
Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients
2021-02-24 13:00 ET
Aytu BioScience to Present at Upcoming March Investor Conferences
2021-02-11 21:01 ET
Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year
2021-02-10 13:00 ET
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
2021-02-10 13:00 ET
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
2021-02-04 13:00 ET
Aytu BioScience to Report Second Fiscal 2021 Results and Provide Business Update on Thursday, February 11, 2021
2020-12-28 13:05 ET
Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients
2020-12-15 17:00 ET
Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
2020-12-14 13:01 ET
Aytu BioScience to Present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET
2020-12-11 04:10 ET
Aytu BioScience Increases Previously Announced Bought Deal Offering to $25.0 Million
2020-12-10 22:35 ET
Aytu BioScience Announces $10.0 Million Bought Deal Offering
2020-12-10 13:00 ET
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company
2020-12-10 11:01 ET
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
2020-11-12 21:01 ET
Aytu BioScience Announces Fiscal Q1 2021 Net Revenue of $13.5 Million, an Increase of 839% Year-Over-Year
2020-11-11 13:00 ET
Aytu BioScience to Present at the Jefferies 2020 Virtual London Healthcare Conference Wednesday, November 18 at 1:45pm ET
2020-11-05 13:00 ET
Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020
2020-10-06 20:02 ET
Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year
2020-10-05 12:00 ET
Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020
2020-09-23 22:00 ET
Aytu BioScience to Reschedule Fourth Quarter and FY 2020 Conference Call
2020-09-16 12:00 ET
Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020
2020-09-08 12:00 ET
Aytu BioScience Announces Global Agreement to Distribute Pinnacle IVD Corporation's 15-Minute COVID-19 Antigen Test
2020-08-19 12:00 ET
Aytu BioScience Announces Launch of Nationwide Mobile COVID-19 Testing Initiative
2020-08-17 12:00 ET
Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study
2020-07-30 12:00 ET
Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration
2020-07-27 12:00 ET
COVID-19 IgG/IgM Rapid Test Cassette Distributed by Aytu BioScience Featured in Business Insider Article
2020-07-20 11:30 ET
Aytu BioScience Announces Expansion of NATESTO(R) U.S. Commercial Team
2020-07-10 12:00 ET
Aytu BioScience Announces Distribution Partnership with Apollo Med Innovations to Expand Distribution of COVID-19 IgG/IgM Rapid Test in United States
2020-06-09 12:00 ET
Aytu BioScience Announces Results from a National Cancer Institute Evaluation of the Company’s Licensed COVID-19 IgG/IgM Rapid Test
2020-06-08 12:00 ET
Aytu BioScience Set to Join Russell 3000(R) Index
2020-06-03 12:00 ET
Aytu BioScience Announces Significant Improvement in Natesto(R) Patient Access in the United States
2020-06-01 20:01 ET
Aytu BioScience Announces $15 Million Debt Retirement
2020-06-01 12:00 ET
Aytu BioScience Announces Emergency Use Authorization of COVID-19 IgG/IgM Rapid Test
2020-05-14 20:01 ET
Aytu BioScience Reports Third Quarter Fiscal 2020 Financial Results
2020-05-07 12:00 ET
Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update
2020-04-30 15:45 ET
Aytu BioScience Announces China Export Clearance of Company's COVID-19 IgG/IgM Rapid Test
2020-04-27 13:55 ET
Aytu BioScience Signs Development Agreement with Sterling Medical Devices to Advance the Development of Healight as a Potential Coronavirus Treatment
2020-04-24 12:00 ET
Aytu BioScience Announces Results from Annual Stockholders Meeting
2020-04-23 12:00 ET
Aytu BioScience Announces Exclusive Distribution Agreement for COVID-19 IgG/IgM Rapid Test with Singapore-Based Biolidics Limited
2020-04-21 12:00 ET
Aytu BioScience Announces Publication of Results from Natesto Spermatogenesis Study in Journal of Urology
2020-04-20 12:00 ET
Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Treatment
2020-04-17 12:25 ET
Aytu BioScience Confirms Export and Incoming Delivery of COVID-19 IgG/IgM Rapid Tests
2020-04-16 12:00 ET
Aytu BioScience Announces Positive Results from an Independently Conducted Clinical Study of the Company's Licensed COVID-19 IgG/IgM Point-of-Care Rapid Test
2020-04-15 12:00 ET
Aytu BioScience Provides Update on its Licensed COVID-19 IgG/IgM Rapid Test Supply and Ongoing U.S. Distribution
2020-04-13 12:00 ET
Aytu BioScience Consumer Health Subsidiary Launches Regoxidine(R), an FDA Approved Hair Regrowth Treatment Foam that Contains 5% Minoxidil and Targets Over 11 Million U.S. Consumers Who Purchased Hair Regrowth Products in 2019
2020-04-09 12:00 ET
Aytu BioScience Announces Updated Annual Shareholder Meeting Date and Virtual Room Access
2020-04-08 12:00 ET
Aytu BioScience Announces Exclusive ZolpiMist(TM) License to Commercialize Aytu's Oral Spray Sleep Aid in South Korea
2020-04-07 12:00 ET
Aytu BioScience Receives $23.0 Million from Warrant Exercises
2020-04-06 12:00 ET
Aytu Featured on NBC and Fox News (VIDEO): "Denver officers, firefighters will be among first in US to get rapid COVID-19 tests"; "Denver scores 2,700 COVID-19 rapid tests for first responders"
2020-04-03 12:00 ET
Aytu BioScience Announces First Commercial Shipment of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test
2020-04-01 12:00 ET
Aytu BioScience Announces Receipt of Initial Shipment of 100,000 COVID-19 IgG/IgM Point-of-Care Rapid Tests; Additional 500,000 Tests on Order
2020-03-30 12:00 ET
AYTU Announces Delay of Annual Meeting of Stockholders Due to Colorado's "Shelter in Place" Order Related to the COVID-19 Crisis
2020-03-25 12:00 ET
Aytu BioScience Regains Compliance with NASDAQ Minimum Bid Price Requirement
2020-03-23 12:00 ET
Aytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test
2020-03-19 16:40 ET
Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market
2020-03-19 12:00 ET
Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico
2020-03-17 15:55 ET
Aytu BioScience Announces Acceleration of U.S. Availability of COVID-19 IgG/IgM Rapid Test Based on Updated FDA Policy
2020-03-16 16:00 ET
Aytu BioScience's Coronavirus Rapid Test Featured on NBC and Fox News (VIDEOS): ''Englewood Company Says It Can Get COVID-19 Test Results in 2-10 Minutes"; "2-Minute COVID-19 Test Results? Denver-Area Company Wants to Deliver That Promise"
2020-03-13 12:00 ET
Aytu BioScience Establishes COVID-19 IgG/IgM Rapid Test Product Inquiry Procedure for Healthcare Professionals and Institutions
2020-03-12 12:00 ET
Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market
2020-03-11 12:00 ET
Aytu Announces $9.0 Million Registered Direct Offering Priced At-the-Market
2020-03-10 12:05 ET
Aytu BioScience Secures Exclusive U.S. Distribution Agreement for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test
2020-02-18 14:00 ET
Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals
2020-02-13 21:10 ET
Aytu Reports Q2 Revenue of $3.2M, Up 77% Year-over-Year and 121% Sequentially
2020-02-06 14:00 ET
Aytu BioScience to Report Fiscal Q2 FY 2020 Results and Business Update
2020-02-05 14:00 ET
Aytu BioScience Announces Acceptance of Results of Two Natesto Clinical Studies for Presentation at American Urological Association Annual Scientific Program
2020-01-28 14:00 ET
Aytu BioScience Announces Acceptance of Natesto Spermatogenesis Study Results for Presentation at ENDO 2020
2020-01-27 14:00 ET
Aytu BioScience and Innovus Pharmaceuticals Announce Effectiveness of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience
2019-12-24 13:05 ET
Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience
2019-12-12 14:13 ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Regarding the November 21, 2019 Preliminary Proxy Statement of AYTU BIOSCIENCE, INC. - AYTU
2019-12-05 11:05 ET
MiOXSYS Male Infertility Test Will be Featured in Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and Medicine
2019-12-03 13:05 ET
Aytu BioScience to Present at LD Micro 12th Annual Main Event Investor Conference on December 11, 2019
2019-12-02 13:05 ET
Aytu BioScience Announces Launch of Natesto(R) U.S. Co-Promotion with Acerus Pharmaceuticals
2019-11-19 13:00 ET
Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading Pharmacy Benefit Manager’s National Formulary
2019-11-14 21:01 ET
Aytu Reports First Quarter 2020 Financial Results
2019-11-11 11:05 ET
Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations
2019-11-07 13:05 ET
Aytu BioScience to Report Fiscal Q1 FY 2020 Results and Business Update
2019-11-04 14:00 ET
Aytu BioScience Announces Closing of $12.4M Prescription Product Portfolio Purchase
2019-10-21 11:01 ET
Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary
2019-10-17 12:30 ET
Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study
2019-10-16 12:30 ET
Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17
2019-10-14 10:30 ET
Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio
2019-10-14 10:15 ET
Aytu BioScience Announces $10 Million Private Placement
2019-10-02 12:05 ET
Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market
2019-09-26 20:02 ET
Aytu BioScience Reports 100% Revenue Growth to $7.3 million in FY 2019
2019-09-24 12:05 ET
Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives
2019-09-19 12:05 ET
Aytu BioScience to Report Fiscal FY 2019 Results and Business Update
2019-09-17 12:05 ET
Aytu BioScience to Present at Ladenburg Thalmann 2019 Healthcare Conference
2019-09-12 12:05 ET
Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals
2019-09-10 12:05 ET
Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in South Africa
2019-09-04 12:05 ET
Aytu BioScience Announces Tuzistra XR Co-Promotion Agreement with Poly Pharmaceuticals
2019-07-30 11:00 ET
Acerus And Aytu Bioscience To Co-Promote NATESTO® In The United States

SEC forms

Show financial reports only

SEC form 8
2024-02-14 00:00 ET
Aytu Biopharma published news for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Aytu Biopharma published news for 2023 q4
SEC form 10
2024-02-14 00:00 ET
Aytu Biopharma reported for 2023 q4
SEC form 8
2023-11-14 16:10 ET
Aytu Biopharma published news for 2023 q3
SEC form 10
2023-11-14 16:05 ET
Aytu Biopharma reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Aytu Biopharma published news for 2023 q3
SEC form 8
2023-10-26 00:00 ET
Aytu Biopharma published news for 2023 q3
SEC form 10
2023-10-12 14:50 ET
Aytu Biopharma published news for 2023 q2
SEC form 10
2023-10-12 00:00 ET
Aytu Biopharma published news for 2023 q2
SEC form 8
2023-09-27 16:20 ET
Aytu Biopharma reported for 2023 q2
SEC form 6
2023-08-15 16:10 ET
Aytu Biopharma published news for 2023 q2
SEC form 6
2023-07-31 08:05 ET
Aytu Biopharma published news for 2023 q2
SEC form 6
2023-07-10 08:05 ET
Aytu Biopharma published news for 2023 q2
SEC form 6
2023-06-15 10:42 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-05-11 16:10 ET
Aytu Biopharma reported for 2023 q1
SEC form 10
2023-05-11 16:03 ET
Aytu Biopharma reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Aytu Biopharma published news for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Aytu Biopharma reported for 2023 q1
SEC form 6
2023-05-01 08:05 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-04-27 08:05 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-04-19 08:00 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-04-07 16:30 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-03-27 16:14 ET
Aytu Biopharma published news for 2022 q4
SEC form 8
2023-02-21 00:00 ET
Aytu Biopharma reported for 2022 q4
SEC form 10
2023-02-21 00:00 ET
Aytu Biopharma reported for 2022 q4
SEC form 8
2022-11-14 00:00 ET
Aytu Biopharma reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Aytu Biopharma reported for 2022 q3
SEC form 8
2022-09-28 00:00 ET
Aytu Biopharma reported for 2022 q2
SEC form 10
2022-09-27 00:00 ET
Aytu Biopharma reported for 2022 q2
SEC form 8
2022-05-16 00:00 ET
Aytu Biopharma reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Aytu Biopharma reported for 2022 q1
SEC form 10
2022-02-14 00:00 ET
Aytu Biopharma published news for 2021 q4
SEC form 8
2022-02-14 00:00 ET
Aytu Biopharma published news for 2021 q4
SEC form 8
2021-11-15 00:00 ET
Aytu Biopharma published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Aytu Biopharma published news for 2021 q3
SEC form 10
2021-09-28 00:00 ET
Aytu Biopharma published news for 2021 q2
SEC form 8
2021-09-27 00:00 ET
Aytu Biopharma published news for 2021 q2
SEC form 10
2021-05-17 00:00 ET
Aytu Biopharma published news for 2021 q1